{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:23:38Z","timestamp":1793229818904,"version":"4.5.0"},"reference-count":26,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ALLERGAN, an ABBVIE company","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Two randomized, placebo-controlled studies evaluated the pulmonary function safety of onabotulinumtoxinA (onabotA) for treatment of upper and\/or lower limb spasticity. Patients with stable baseline respiratory status received one or two treatments with placebo, 240 U, or 360 U of onabotA. Pulmonary function tests, adverse events, and efficacy were measured at least every 6 weeks for 18 weeks (Study 1) or 30 weeks (Study 2). Study 1 enrolled 109 patients (n = 36\u201337\/group) and Study 2 enrolled 155 patients (n = 48\u201354\/group). Mean baseline forced vital capacity (FVC) was 76\u201378% of predicted per group in Study 1 and 71% of predicted per group in Study 2. In Study 1, change from baseline FVC values were significantly (p &lt; 0.05) decreased vs. placebo at weeks 3 (240 U \u221257 mL vs. placebo +110 mL) and 12 (360 U \u22126 mL vs. +167 mL placebo). In Study 2, change from baseline FVC values were significantly decreased in the 360 U group vs. placebo at weeks 6 (\u221278 mL vs. +49 mL placebo), 13 (\u221260 mL vs. +119 mL placebo), 18 (\u2212128 mL vs. +80 mL placebo), and 24 (\u221282 mL vs. +149 mL placebo). Individual pulmonary function-related adverse events were not correlated with PFT decreases. The most frequent pulmonary-related adverse events were nasopharyngitis (Study 1) and upper respiratory tract infection (Study 2). Ashworth scores were significantly improved at multiple time points in both studies. Injection of onabotA for spasticity in patients with decreased pulmonary function, at single and repeated doses of up to 360 U, was associated with small but statistically significant decreases in FVC or forced expiratory volume 1 s (FEV1) (&gt;12% and 200 mL) that were subclinical and not correlated with any adverse clinical pulmonary events.<\/jats:p>","DOI":"10.3390\/toxins12100661","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T20:44:41Z","timestamp":1603140281000},"page":"661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA"],"prefix":"10.3390","volume":"12","author":[{"given":"Ziyad","family":"Ayyoub","sequence":"first","affiliation":[{"name":"Rancho Los Amigos National Rehabilitation Center, Downey, CA 90242, USA"},{"name":"Clinical Professor of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA"},{"name":"Department of Physical Medicine and Rehabilitation, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8812-7545","authenticated-orcid":false,"given":"Allison","family":"Brashear","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jagiellonian University, 31-007 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schoene","sequence":"additional","affiliation":[{"name":"Sound Physicians, San Francisco, CA 95116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-6728","authenticated-orcid":false,"given":"William","family":"Stringer","sequence":"additional","affiliation":[{"name":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Boodhoo","sequence":"additional","affiliation":[{"name":"Allergan plc, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Yushmanova","sequence":"additional","affiliation":[{"name":"Allergan plc, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Allergan plc, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1989-6076","authenticated-orcid":false,"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan plc, an AbbVie Company, Irvine, CA 92612, USA"},{"name":"Department of Neurology, University of California, Irvine, CA 92697, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa011892","article-title":"Botox Post-Stroke Spasticity Study, G. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke","volume":"347","author":"Brashear","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ene.12381","article-title":"Early botulinum toxin treatment for spastic pes equinovarus--a randomized double-blind placebo-controlled study","volume":"21","author":"Fietzek","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome","volume":"67","author":"Esquenazi","year":"2013","journal-title":"Toxicon"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1017\/cjn.2015.314","article-title":"Adverse Clinical Effects of Botulinum Toxin Intramuscular Injections for Spasticity","volume":"43","author":"Phadke","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.apmr.2006.02.015","article-title":"Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity","volume":"87","author":"Turkel","year":"2006","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/16501970500415348","article-title":"Focal spasticity therapy with botulinum toxin: Effects on function, activities of daily living and pain in 100 adult patients","volume":"38","author":"Bergfeldt","year":"2006","journal-title":"J. Rehabil. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1047-9651(03)00093-7","article-title":"Muscle overactivity and movement dysfunction in the upper motoneuron syndrome","volume":"14","author":"Mayer","year":"2003","journal-title":"Phys. Med. Rehabil. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1590\/0004-282x20190048","article-title":"Relationship between pulmonary function, functional independence, and trunk control in patients with stroke","volume":"77","author":"Santos","year":"2019","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/0003-9993(94)90378-6","article-title":"2. Comorbidities and complications","volume":"75","author":"Roth","year":"1994","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1468-1331.2000.00104.x","article-title":"Assessment of corticodiaphragmatic pathway and pulmonary function in acute ischemic stroke patients","volume":"7","author":"Khedr","year":"2000","journal-title":"Eur. J. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.resp.2009.04.002","article-title":"Pulmonary function and spinal cord injury","volume":"166","author":"Schilero","year":"2009","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.23736\/S1973-9087.16.04329-X","article-title":"Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: A systematic review with meta-analysis and trial sequential analysis","volume":"53","author":"Dong","year":"2017","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"ref_13","first-page":"521","article-title":"Spasticity treatment with onabotulinumtoxin A: Data from a prospective German real-life patient registry","volume":"121","author":"Schramm","year":"2014","journal-title":"J. Neural. Transm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity","volume":"26","author":"Kaji","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","article-title":"Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke","volume":"85","author":"Childers","year":"2004","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1212\/WNL.0000000000003789","article-title":"Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study","volume":"88","author":"Wissel","year":"2017","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.21053\/ceo.2016.00241","article-title":"Electromyography-Guided Botulinum Toxin Injection into the Cricothyroid Muscles in Bilateral Vocal Fold Abductor Paralysis","volume":"10","author":"Sahin","year":"2017","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00415-002-0702-8","article-title":"Distribution and course of cortico-respiratory projections for voluntary activation in man. A transcranial magnetic stimulation study in healthy subjects and patients with cerebral ischemia","volume":"249","author":"Urban","year":"2002","journal-title":"J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1620\/tjem.245.79","article-title":"Decreased Respiratory Muscle Function Is Associated with Impaired Trunk Balance among Chronic Stroke Patients: A Cross-sectional Study","volume":"245","author":"Lee","year":"2018","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1161\/STROKEAHA.113.003342","article-title":"Stroke alters respiratory burst in neutrophils and monocytes","volume":"45","author":"Ruhnau","year":"2014","journal-title":"Stroke"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12974-014-0213-4","article-title":"Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke","volume":"11","author":"Winklewski","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/brain\/awv375","article-title":"Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level","volume":"139","author":"Brommer","year":"2016","journal-title":"Brain"},{"key":"ref_24","first-page":"659","article-title":"Reference spirometric values using techniques and equipment that meet ATS recommendations","volume":"123","author":"Crapo","year":"1981","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_25","first-page":"1348","article-title":"The assessment of maximal respiratory mouth pressures in adults","volume":"54","author":"Evans","year":"2009","journal-title":"Respir. Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/rmed.2000.0802","article-title":"Maximal inspiratory mouth pressures (PIMAX) in healthy subjects\u2014What is the lower limit of normal?","volume":"94","author":"Hautmann","year":"2000","journal-title":"Respir. Med."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/10\/661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:24:15Z","timestamp":1760178255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/10\/661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["toxins12100661"],"URL":"https:\/\/doi.org\/10.3390\/toxins12100661","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]}}}